FMC Foley is a medicare approved dialysis facility center in Foley, Alabama and it has 16 dialysis stations. It is located in Baldwin county at 230 East Fern Avenue, Foley, AL, 36535. You can reach out to the office of FMC Foley at (251) 943-1500. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Foley has the following ownership type - Profit. It was first certified by medicare in September, 2009. The medicare id for this facility is 012634 and it accepts patients under medicare ESRD program.
| Name | FMC Foley |
|---|---|
| Location | 230 East Fern Avenue, Foley, Alabama |
| No. of Dialysis Stations | 16 |
| Medicare ID | 012634 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 230 East Fern Avenue, Foley, Alabama, 36535 | |
| (251) 943-1500 | |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
| NPI Number | 1194963777 |
| Organization Name | Fresenius Medical Care Foley |
| Doing Business As | Bio-medical Applications Of Alabama, Inc. |
| Address | 230 East Fern Ave. Foley, Alabama, 36535 |
| Phone Number | (251) 943-1500 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 79% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 13% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 8% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 14% |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 69% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 16% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 15% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 84% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 16% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 70% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 20 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 58 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 497 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Foley with elevated calcium levels.
| Patients with hypercalcemia | 60 |
| Hypercalcemia patient months | 513 |
| Patients with Serumphosphor | 67 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 117 |
| Patient months included in arterial venous fistula and catheter summaries | 390 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 48 |
| Hospitalization Rate in facility | 193.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 340.6 |
| Hospitalization Rate: Lower Confidence Limit | 113.9 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Foley were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.4 |
| Readmission Rate: Lower Confidence Limit | 11.6 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Foley get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .64 (As Expected) |
| SIR: Upper Confidence Limit | 2.1 |
| SIR: Lower Confidence Limit | .11 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Foley's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 39 |
| Transfusion Rate in facility | 46.3 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 134.5 |
| Transfusion Rate: Lower Confidence Limit | 18.2 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Foley lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 198 |
| Mortality Rate in facility | 10.7 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 16.5 |
| Mortality Rate: Lower Confidence Limit | 6.5 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago
South Baldwin Dialysis Center Location: 150 W Peachtree Ave, Foley, Alabama, 36535 Phone: (251) 943-4155 |
News Archive
Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.
BC Children's Hospital and University of British Columbia (UBC) researchers have found that two existing screening tests are accurate in diagnosing development delays in children and could be incorporated in a busy family practice setting with relative ease.
Lowell General Physician-Hospital Organization, a 280-physician integrated delivery system providing outstanding quality care to patients in the Greater Lowell (Massachusetts) area, has implemented MedVentive's award-winning technology platform to manage risk and quality performance. To effectively manage its capitated and incentive-based quality contracts with multiple payers, Lowell PHO sought a comprehensive, flexible technology platform to manage risk, identify improvement opportunities, and proactively outreach to its physicians and patients.
Bright Instruments will exhibit its new OTF5500 Touch Screen for the first time in public next week at the IBMS Congress (28-30 Sept 2015, Stand 800) in Birmingham UK. This is a significant update to the existing OTF 5000.
› Verified 2 days ago